ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Longeveron Inc

Longeveron Inc (LGVN)

2.91
-0.23
( -7.32% )
Updated: 13:27:49

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
2.91
Bid
2.90
Ask
2.91
Volume
1,240,972
2.88 Day's Range 3.19
0.7707 52 Week Range 35.60
Market Cap
Previous Close
3.14
Open
3.10
Last Trade
1
@
2.91
Last Trade Time
13:27:49
Financial Volume
$ 3,760,669
VWAP
3.0304
Average Volume (3m)
10,829,152
Shares Outstanding
6,348,624
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About Longeveron Inc

Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome ... Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and Hypoplastic left heart syndrome (HLHS). Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Longeveron Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LGVN. The last closing price for Longeveron was $3.14. Over the last year, Longeveron shares have traded in a share price range of $ 0.7707 to $ 35.60.

Longeveron currently has 6,348,624 shares outstanding. The market capitalization of Longeveron is $19.93 million.

LGVN Latest News

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular...

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular...

Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease

– FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ – – Second designation received for Lomecel-B™ for the treatment of mild Alzheimer’s Disease...

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease

MIAMI, July 10, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for certain life-threatening...

Neha Motwani Elected to Longeveron® Board of Directors

MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and...

Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and...

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual...

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.98-25.19280205663.894.882.850284680213.72439229CS
41.0455.6149732621.876.391.46114268103.95902405CS
121.2474.2514970061.676.390.7707108291523.06913116CS
26-5.962-67.20018034278.87290.770760901023.03826236CS
52-31.39-91.516034985434.335.60.770731668923.76111863CS
156-59.89-95.366242038262.84500.7707263541798.00649315CS
260-97.09-97.091004500.7707236742797.29527166CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DCAPUnity Wealth Partners Dynamic Capital Appreciation & Options ETF
 20.10
(839.25%)
128.77k
RGCRegencell Bioscience Holdings Ltd
$ 26.97
(700.30%)
333.62k
SLRXSalarius Pharmaceuticals Inc
$ 4.22
(174.03%)
53M
ATPCAgape ATP Corporation
$ 0.2176
(52.17%)
95.96M
SPWRSunPower Corporation
$ 1.022
(42.78%)
145.67M
FLYEFly E Group Inc
$ 1.54
(-75.86%)
12.16M
RNAZTransCode Therapeutics Inc
$ 0.30
(-62.15%)
7.67M
JAGXJaguar Health Inc
$ 1.85
(-56.67%)
13.73M
MIRAMIRA Pharmaceuticals Inc
$ 2.50
(-50.10%)
22.94M
SLNASelina Hospitality PLC
$ 0.0249
(-32.70%)
116.89M
ADILAdial Pharmaceuticals Inc
$ 1.47
(38.68%)
154.3M
SPWRSunPower Corporation
$ 1.022
(42.78%)
145.67M
SLNASelina Hospitality PLC
$ 0.0249
(-32.70%)
116.89M
NVDANVIDIA Corporation
$ 122.885
(-0.53%)
111.52M
ATPCAgape ATP Corporation
$ 0.2176
(52.17%)
95.96M

LGVN Discussion

View Posts
Monksdream Monksdream 2 days ago
LGVN under $4
👍️0
tbonaces80 tbonaces80 4 days ago
Nibble here gap filled
👍️0
Invest-in-America Invest-in-America 6 days ago
WRONG!!! This PLANET needs to acquire at least a PALTRY knowledge about our Human GENOME!!! The answer to Human AGING & 'Old Timers' disease is in our GENOMES!!! And NOT in the nonsense IGNORANCE of firms like LGVN!!!
👍️0
PonkenPlonken PonkenPlonken 6 days ago
u need to increase your knowledge on the matter.
👍️0
Invest-in-America Invest-in-America 6 days ago
I understand that, but LGVN is NOT a very "real entity" in any respect. (If they were, they would NOT publish such petty events.)
👍️0
PonkenPlonken PonkenPlonken 6 days ago
pretty
👍️0
PonkenPlonken PonkenPlonken 6 days ago
That is not how it works, the FDA is a very real entity.
👍️0
Monksdream Monksdream 6 days ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
Invest-in-America Invest-in-America 6 days ago
LGVN: And yet MORE fluff 'news' from this circus show!! (Heck, they PR purported 'news' after they simply TURN-ON-THE-LIGHTS at their headquarters!!! Oh boy, and today they purportedly got FDA "Fast Track"; and last week it was FDA "Medium Track"; and next week they will get FDA "Ultra-Track" designation. Fluck this firm!!)
👍️0
glenn1919 glenn1919 1 week ago
LGVN...................................https://stockcharts.com/h-sc/ui?s=LGVN&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 2 weeks ago
LGVN...$4.44...Starting up again after $3.80 range dip...Hit $7 plus days ago...🥳
👍️0
tbonaces80 tbonaces80 2 weeks ago
Tier 1 buy in. Double from here
👍️0
PirateLeviathan8 PirateLeviathan8 2 weeks ago
Nice move
the shorts are probably going backwards
👍️0
TIMGZ TIMGZ 2 weeks ago
WHAT A BLESSING, EXCELLENT PRICE ACTION. THANKS*** OUT FOR NOW AND RE ENTER WITH TIME ***
👍️0
PirateLeviathan8 PirateLeviathan8 2 weeks ago
thanks so lot for you kindness !!!

and you ?
you are the hero here, there talk behind and is very clever and the hero
👍️0
PirateLeviathan8 PirateLeviathan8 2 weeks ago
look at the chart, so we see resistant in the way up, a small one by 4,21 and 4,57 and a stronger one by 5,06.... after the 5,06 we are open until 6,50 and 8,24 ... a short can change very quick in the other direction and the stock price flip very quick up
👍️ 1
10KidsR1000 10KidsR1000 2 weeks ago
Looking at the 2 year PPS chart and considering the recent FDA news, I see a huge comeback in the making.
👍️0
Zardiw Zardiw 2 weeks ago
$KZIA +248% #DDAmanda Video Analysis - #1 Stock Scanner/Screener



Z
👍️0
XenaLives XenaLives 2 weeks ago
Perhaps this is just a big pump to find bagholders so shorts can cover and move on...


👍️0
XenaLives XenaLives 2 weeks ago
Your posts are devoid of any intelligent comment...

Don't flatter yourself... I wasn't searching you out, but your idiocy was obvious on the replied to thread.
👍️0
Invest-in-America Invest-in-America 2 weeks ago
LGVN: And, of course, YOU are still dating Hercules, right???

////////////////////////////////////////////////////////////////////////////////////////////////////////
👍️0
XenaLives XenaLives 2 weeks ago
... and you also have a bridge for sale I suppose,,,,,,
👍️0
PirateLeviathan8 PirateLeviathan8 2 weeks ago
follow the money....not the news

103 million volume is a clear since where we go tomorrow....it´s only a question how high we jump over 6 bucks
👍️ 1
PirateLeviathan8 PirateLeviathan8 2 weeks ago
5,42 end of the day is possible
tomorrow we see a runner over 7 bucks and more
👍️0
Invest-in-America Invest-in-America 2 weeks ago
LGVN: Perhaps a little sign of LIFE here now, suddenly?? (Our USA President --- Mr. Joe --- desperately needs LGVN's stuff!!!)
👍️ 1 😵 1
Invest-in-America Invest-in-America 2 weeks ago
LGVN: So., Capt. Tim, you too were dumb enough --- like me --- to buy this garbage!!! (And evidently, we BOTH were so stupid that we MISSED the EASY bucks over on that @KZIA monster runner today!!!!)
👎️ 1 💩 1 🚽 1 🤡 1
TIMGZ TIMGZ 2 weeks ago
I CUT THE KNIEF HERE, SHOULD ALMOST BE DONE WITH DILUTION AND I CAN GET OUT*** GREEDINESS
👍️0
Invest-in-America Invest-in-America 2 weeks ago
LGVN: Evidently, 'Old Timers' disease, Senile Dementia, inter alia, just ain't TRENDING anymore!!! (Maybe because their PR merely referred to "MILD" cases of 'Old Timers' disease --- vs. severely-advanced cases thereof, like with our (babbling) President Joe!!! And I'm a full-blown DEMOCRAT saying that!!!)
👎️ 1 💩 1 🚽 1 🤡 1
Dantheoneman Dantheoneman 2 weeks ago
lol
👍️0
Invest-in-America Invest-in-America 2 weeks ago
LGVN: Meaning "wee-wee", or like PISS down the toilet??? (What a P.O.S. turd this turned out to be!!!)
👎️ 1 💩 1 🚽 1 🤡 1
Dantheoneman Dantheoneman 2 weeks ago
Weeeeeee
👍️0
Invest-in-America Invest-in-America 2 weeks ago
Only LGVN right now, Bro.
👍️0
XenaLives XenaLives 2 weeks ago
Impressive, also testimony to how unrelated market pricing is to fundamentals. See charts at bottom.


Phase 2 clinical trial underway for Hypoplastic Left Heart Syndrome, which affects approximately 1,000 babies per year

MIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants. Lomecel-B, an investigational allogeneic, bone marrow-derived medicinal signaling cell (MSC) product, is currently being evaluated in a Phase 2 trial.


“We are pleased by FDA’s acknowledgment of the urgent need for a safe and effective treatment for children born with this rare and devastating congenital heart defect,” stated Longeveron co-founder and Chief Science Officer Joshua M. Hare, M.D. “We are encouraged by our Phase 1 clinical data, and the progress being made in the ongoing Phase 2 trial. Lomecel-B represents a unique cell therapy approach that could potentially be administered at the same time as surgery in these critically impacted infants.”

Approximately 1,000 babies are born with HLHS each year in the U.S. HLHS babies have an underdeveloped left ventricle, which impairs the heart’s ability to pump blood throughout the body. HLHS is often fatal without surgical intervention, in which three surgical procedures are performed over the period of about 5 years, to allow the right ventricle to be configured to pump blood to the body. Longeveron is evaluating the safety of Lomecel-B injection into the right ventricle during the second surgery (4 – 6 months of age), and the effect on cardiac function and other health status endpoints.

Longeveron recently reported clinical results from its safety-focused Phase I clinical study of Lomecel-B in HLHS patients. When cardiac surgeons injected Lomecel-B directly into the babies’ hearts at the time of surgery, the cells were well tolerated with no major adverse cardiac events and no infections considered to be related to the investigational treatment.

One hundred percent of infants enrolled in the Phase 1 trial (n=10) were alive and had not required a transplant between 2 – 3.5 years post-surgery. Other measurements of the babies’ health, such as weight gain and growth pattern, matched that of normal healthy babies.

The FDA may grant RPD designation for diseases that primarily affect children ages 18 years old or younger, and fewer than 200,000 individuals in the U.S. Under this program, if the FDA approves Lomecel-B for the treatment of HLHS, Longeveron may be eligible to receive a priority review voucher (PRV) if the application submitted for the product satisfies certain conditions, and under current law, is approved prior to September 30, 2026. Drug companies receiving a PRV can have any subsequent drug or biologic application reviewed and a decision made in six months as opposed to the standard 10 months, potentially accelerating the time to market, or they can sell the PRV to another company. The PRV accelerated review is for patients with serious conditions providing access to a potentially lifesaving or -changing treatment sooner. For companies, it means they can potentially go to market with their product more quickly, and potentially begin generating product revenue.

Infants with HLHS are currently being enrolled in ELPIS II, a 38-subject, phase 2 randomized, double-blind, controlled clinical trial. ELPIS II is being funded in part by a grant from the National Institute of Health’s National Heart, Lung, and Blood Institute (NHLBI; Grant number 1UG3HL148318), in collaboration with Longeveron, and is led by Principal Investigator Sunjay Kaushal, MD, PhD, Division Head, Cardiovascular-Thoracic Surgery, Ann and Robert H. Lurie Children’s Hospital of Chicago. Other participating clinical sites currently open for enrollment are Advocate Children’s Hospital, Park Ridge, IL; Primary Children’s Hospital/University of Utah, Salt Lake City, UT; Children’s Hospital Los Angeles, Los Angeles, CA; and Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.




https://finance.yahoo.com/news/u-food-drug-administration-approves-130000821.html?fr=yhssrp_catchall







👍️0
georgie18 georgie18 2 weeks ago
LGVN...$6.22...Watch for $9 here...🥳
👍️0
Awl416 Awl416 2 weeks ago
Don’t blink
👍️0
georgie18 georgie18 2 weeks ago
LGVN...$5.26...200MA at $9.40 range...🥳
👍️0
georgie18 georgie18 2 weeks ago
LGVN...$4.70s clearing here...🥳
👍️0
georgie18 georgie18 2 weeks ago
LGVN...$4.02...🥳
👍️0
georgie18 georgie18 2 weeks ago
LGVN...$3.70...Off the $2.23...Alert...🥳

georgie18

Member Level
Re: georgie18 post# 251

Tuesday, July 09, 2024 10:36:32 AM

Post#
253
of 255
LGVN...$2.89...Psar flipped Bullish as LGVN taps the Upper Band...🥳

georgie18

Member Level
Re: None

Monday, July 08, 2024 6:55:48 PM

Post#
251
of 252
LGVN...$2.23...Bouncing off the 50ma post dip in the $1.50 range...🥳
👍️ 1
Awl416 Awl416 2 weeks ago
Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease
👍️0
boston127 boston127 2 weeks ago
How many stocks do you own?

Every time I go to a board where a stock has skyrocketed, you are there.
👍️0
georgie18 georgie18 2 weeks ago
LGVN...$2.89...Psar flipped Bullish as LGVN taps the Upper Band...🥳

georgie18

Member Level
Re: None

Monday, July 08, 2024 6:55:48 PM

Post#
251
of 252
LGVN...$2.23...Bouncing off the 50ma post dip in the $1.50 range...🥳
👍️0
Invest-in-America Invest-in-America 2 weeks ago
LGVN: At this point, I am relatively HAPPY that I grabbed this cute little puppy earlier today!! (And I hope that I am NOT weeping, later today.)
👍️0
georgie18 georgie18 2 weeks ago
LGVN...$2.23...Bouncing off the 50ma post dip in the $1.50 range...🥳
👍️0
glenn1919 glenn1919 2 weeks ago
LGVN............................https://stockcharts.com/h-sc/ui?s=LGVN&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 2 weeks ago
LGVN under $2
👍️0
Monksdream Monksdream 1 month ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
Awl416 Awl416 1 month ago
Professional short squeeze
👍️0
glenn1919 glenn1919 1 month ago
LGVN..............................https://stockcharts.com/h-sc/ui?s=LGVN&p=W&b=5&g=0&id=p86431144783
👍️0
Dantheoneman Dantheoneman 1 month ago
lol
👍️0

Your Recent History

Delayed Upgrade Clock